Pyrvinium
Pyrvinium is a cyanine dye antiparasitic agent that inhibits the NADH-fumarate reductase mitochondrial electron transport chain of helminths, disrupting their glucose uptake and aerobic metabolism, causing paralysis and death of the parasite. It is used for the treatment of pinworm (enterobiasis) infections, and more recently has been investigated as an antineoplastic agent targeting the Wnt signaling pathway in cancer, including pancreatic cancer.
分子量
382.5000 g/mol
LogP
5.90
TPSA
12.10 Ų
リピンスキーの五則
適合
治療領域
作用機序
Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.
2D構造
Cite this structure
Embed this structure
SMILES
Cc1cc(/C=C/c2ccc3cc(N(C)C)ccc3[n+]2C)c(C)n1-c1ccccc1
InChI
InChI=1S/C26H28N3/c1-19-17-21(20(2)29(19)24-9-7-6-8-10-24)11-13-23-14-12-22-18-25(27(3)4)15-16-26(22)28(23)5/h6-18H,1-5H3/q+1
Molecular Formula
C26H28N3+
HBD / HBA
- / 1
回転可能結合数
4
重原子数
29
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
Pyrvinium is a cyanine dye antiparasitic agent that inhibits the NADH-fumarate reductase mitochondrial electron transport chain of helminths, disrupting their glucose uptake and aerobic metabolism, causing paralysis and death of the parasite. It is used for the treatment of pinworm (enterobiasis) infections, and more recently has been investigated as an antineoplastic agent targeting the Wnt signaling pathway in cancer, including pancreatic cancer.
Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.
Yes, Pyrvinium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201303. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5281035. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="pyrvinium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/pyrvinium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/pyrvinium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/pyrvinium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="pyrvinium"></drugfyi-drug>